Featured NewsNovo Nordisk reveals obesity drug with up to 22 percent weight lossmanamalive.comJanuary 24, 2025January 24, 2025 by manamalive.comJanuary 24, 2025January 24, 20250233 Novo Nordisk shares surged 6.87% to $86.67 on Friday morning following the release of promising trial results for its new obesity treatment, amycretin. The company reported that the drug demonstrated significant weight-loss effects during a...